Schedule 13G ownership disclosure

Tango Therapeutics Inc

Common Stock, $0.001 par value per share · CUSIP: 87583X109

Event date: 2025-09-19

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Invus Public Equities, L.P.

    Shares: 5,082,716.00 · Class: 4.6%

  • Invus Public Equities Advisors, LLC

    Shares: 5,082,716.00 · Class: 4.6%

  • Invus Global Management, LLC

    Shares: 5,082,716.00 · Class: 4.6%

  • Siren, L.L.C.

    Shares: 5,082,716.00 · Class: 4.6%

  • Avicenna Life Sci Master Fund LP

    Shares: 800,472.00 · Class: 0.7%

  • Avicenna Life Sci Master GP LLC

    Shares: 800,472.00 · Class: 0.7%

  • Ulys, L.L.C.

    Shares: 800,472.00 · Class: 0.7%

  • Raymond Debbane

    Shares: 5,883,188.00 · Class: 5.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002005369-25-000050
Form type
SCHEDULE 13G
Filer
Invus Global Management, LLC
CIK
CIK 2005369
Filed
Sep 22, 2025
Reporting period
Sep 19, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub